Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Leases: 2019-2024

Historic Operating Leases for Cumberland Pharmaceuticals (CPIX) over the last 6 years, with Dec 2024 value amounting to $5.3 million.

  • Cumberland Pharmaceuticals' Operating Leases fell 7.27% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 7.27%. This contributed to the annual value of $5.3 million for FY2024, which is 6.17% down from last year.
  • According to the latest figures from FY2024, Cumberland Pharmaceuticals' Operating Leases is $5.3 million, which was down 6.17% from $5.6 million recorded in FY2023.
  • In the past 5 years, Cumberland Pharmaceuticals' Operating Leases ranged from a high of $5.6 million in FY2023 and a low of $1.1 million during FY2021.
  • For the 3-year period, Cumberland Pharmaceuticals' Operating Leases averaged around $5.2 million, with its median value being $5.3 million (2024).
  • In the last 5 years, Cumberland Pharmaceuticals' Operating Leases tumbled by 48.97% in 2021 and then surged by 349.11% in 2022.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Operating Leases stood at $2.1 million in 2020, then crashed by 48.97% to $1.1 million in 2021, then skyrocketed by 349.11% to $4.8 million in 2022, then rose by 18.60% to $5.6 million in 2023, then declined by 6.17% to $5.3 million in 2024.